scholarly journals A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

2013 ◽  
Vol 24 (2) ◽  
pp. 329-336 ◽  
Author(s):  
A. Heidenreich ◽  
S.K. Rawal ◽  
K. Szkarlat ◽  
N. Bogdanova ◽  
L. Dirix ◽  
...  
Keyword(s):  
Human Monoclonal Antibody ◽  
Line Treatment ◽  
Phase 2 ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Double Blind ◽  
Castration Resistant ◽  
Multicenter Phase ◽  
Phase 2 Study ◽  
First Line Treatment

A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS8130-TPS8130
Author(s):  
David R. Spigel ◽  
Fred R. Hirsch ◽  
Richard H. De Boer ◽  
Ronald B. Natale ◽  
Jeffrey Crawford ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Double Blind ◽  
Phase 2 Trial ◽  
Multicenter Phase ◽  
First Line Treatment

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

2020 ◽  
Vol 20 (3) ◽  
pp. 228-237 ◽  
Author(s):  
Noha Rashad ◽  
Thoraya Abdelhamid ◽  
Samia A. Shouman ◽  
Hanan Nassar ◽  
Mervat A. Omran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Study ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document